1. Sarcopenia as a Predictive Factor for Carboplatin Toxicity in Patients with Advanced Non-Small Cell Lung Cancer.
- Author
-
Turcott JG, Miyagui SM, Gutiérrez Torres S, Cárdenas-Fernández D, Caballé-Perez E, Rios-Garcia E, Cardona AF, Rolfo C, and Arrieta O
- Subjects
- Humans, Female, Male, Aged, Middle Aged, Antineoplastic Agents adverse effects, Tomography, X-Ray Computed, Retrospective Studies, Muscle, Skeletal drug effects, Muscle, Skeletal pathology, Muscle, Skeletal diagnostic imaging, Carboplatin adverse effects, Carboplatin administration & dosage, Carcinoma, Non-Small-Cell Lung drug therapy, Carcinoma, Non-Small-Cell Lung complications, Sarcopenia chemically induced, Lung Neoplasms drug therapy
- Abstract
Sarcopenia in cancer patients often negatively impacts various outcomes. Carboplatin, a first-line chemotherapy for non-small cell lung cancer (NSCLC), is dosed based on body weight, which doesn't account for sarcopenia. This study evaluated the association between sarcopenia and carboplatin-related toxicity in NSCLC patients. Patients with locally advanced or metastatic NSCLC treated with carboplatin were included. Toxicity events during the first two cycles of treatment were recorded. Sarcopenia was assessed using pretreatment computed tomography scans analyzed with Slice-O-Matic V4.2 software, defining sarcopenia as a skeletal muscle index (SMI) of <52.4 cm
2 /m2 for men and <38.5 cm2 /m2 for women. Among 146 patients, 52% had sarcopenia. Hematological toxicity occurred in 71.2% of all patients and 77.6% of those with sarcopenia. The fat-free mass index (FFMI) was independently associated with hematological toxicity and dose-limiting toxicity (DLT), which was observed in 55.5% of patients. Sarcopenia significantly correlates with hematological toxicity and DLT during carboplatin treatment in NSCLC patients. Given its prevalence and noninvasive detection, further research is needed to understand its impact on treatment outcomes.- Published
- 2024
- Full Text
- View/download PDF